Lipid nanomaterials and uses thereof

Patent metadata

Field	Value
Publication number	US-2024254076-A1
Application number	US-202218557218-A
Country	US
Kind code	A1
Filing date	Apr 26, 2022
Priority date	Apr 26, 2021
Publication date	Aug 1, 2024
Grant date	—

Abstract

Disclosed herein are lipid formulations that can be used in drug delivery and screening.

First claim

1 . A compound represented by any one of Formulas I through XIX, or a pharmaceutically acceptable salt thereof:

wherein
R 1 , R 2 , R 3 , and R 4 are each independently a substituted or unsubstituted C 1 -C 20 alkyl;
R 5 and R 14 are each independently hydrogen, a substituted or unsubstituted C 1 -C 5 alkyl;
R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are each independently hydrogen, OH, halogen, or substituted or unsubstituted C 1 -C 5 alkyl;
R 15 , R 16 , and R 17 are each independently hydrogen, OH, halogen, or substituted or unsubstituted C 1 -C 5 alkyl; and
R 18 is OH or substituted or unsubstituted C 1 -C 10 alkyl.

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . The compound of claim 1 , wherein the compound is represented by any one of Formulas I-A through XIX-A:

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are each independently a substituted or unsubstituted C 5 -C 15 alkyl.

14 . (canceled)

15 . (canceled)

16 . The compound of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are each independently a linear or branched C 5 -C 15 alkyl substituted with one or more substituents selected from the group consisting of ester, ether, carbonate ester, acetal, ketal, thioketal, thiol, sulfide, disulfide, diols, oxo, and amides.

17 . The compound of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of:

wherein N, M, and X each independently represent integers from 1 to 9.

18 . (canceled)

19 . The compound of claim 1 , wherein at least one of R 1 , R 2 , R 3 , and R 4 comprise:

wherein N and M each independently represent integers from 1 to 9.

20 . The compound of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 each comprise

wherein N and M each independently represent integers from 1 to 9.

21 . The compound of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of:

22 . (canceled)

23 . The compound of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are all the same.

24 . The compound of claim 1 , wherein the compound is selected from any one of the structures depicted in BL1-BL83:

25 . (canceled)

26 . (canceled)

27 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

28 . The compound of claim 1 , wherein the compound comprises:

or a pharmaceutically acceptable salt thereof.

29 . The compound of claim 1 , wherein the compound comprises:

or a pharmaceutically acceptable salt thereof.

30 . The compound of claim 1 , wherein the compound comprises:

or a pharmaceutically acceptable salt thereof.

31 . The compound of claim 1 , wherein the compound comprises:

or a pharmaceutically acceptable salt thereof.

32 . The compound of claim 1 , wherein the compound comprises:

or a pharmaceutically acceptable salt thereof.

33 . The compound of claim 1 , wherein the compound comprises:

or a pharmaceutically acceptable salt thereof.

34 . (canceled)

35 . A lipid particle comprising the compound of claim 1 .

36 . (canceled)

37 . (canceled)

38 . (canceled)

39 . (canceled)

40 . (canceled)

41 . A pharmaceutical composition comprising a therapeutical agent encapsulated within the lipid particle of claim 35 .

42 . (canceled)

43 . (canceled)

44 . (canceled)

45 . (canceled)

46 . (canceled)

47 . A method o

Assignees

• Ohio State Innovation Foundation

Inventors

• Dong Yizhou
• Wang Chang
• Zhang Yuebao
• Xue Yonger

Classifications

• C07D487/04

  Ortho-condensed systems · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D209/20

  substituted additionally by nitrogen atoms, e.g. tryptophane · CPC title

• C07C317/30

  with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton · CPC title

• C07C237/08

  having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms · CPC title